Intec Pharma registers $46 million of stock for an initial public sale

Maxim Group and Roth Capital Partners will be the joint bookrunners

By Devika Patel

Knoxville, Tenn., June 9 – Intec Pharma Ltd. will conduct an initial public offering of its ordinary stock with a 45-day greenshoe, according to a Form F-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $46 million of stock.

Maxim Group LLC and Roth Capital Partners, LLC are the bookrunners.

Proceeds will be used for pre-commercialization and commercialization activities, development, enhancements and general corporate purposes, including working capital, general and administrative matters and other capital expenditures.

The biopharmaceutical company is based in Jerusalem. The company intends to list its common stock on the Nasdaq.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.